Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ºñ¼Ò¼¼Æ÷¼º Æó¾ÏÀÇ ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á Postoperative Radiotherapy for Non-Small cell Lung Cancer

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2001³â 19±Ç 2È£ p.113 ~ 117
ÀüÇÏÁ¤, À̸íÀÚ,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀüÇÏÁ¤ (  ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç

À̸íÀÚ (  ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç

Abstract

¸ñÀû: ºñ¼Ò¼¼Æ÷¼º Æó¾Ï ȯÀÚ¿¡¼­ ¼ö¼úÈÄ ¹æ»ç¼±Ä¡·á°¡ »ýÁ¸À² ¹× ±¹¼ÒÁ¦¾îÀ²¿¡ ¹ÌÄ¡´Â È¿°ú¸¦ Æò°¡ÇÏ°íÀÚ ÇÔÀÌ º» ¿¬±¸ÀÇ ¸ñÀûÀÌ´Ù.
Àç·á ¹× ¹æ¹ý: 1987³â 5¿ùºÎÅÍ 1999³â 10¿ù±îÁö ±ÙÄ¡Àû ¼ö¼úÈÄ ¿ÜºÎ ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÑ
N1 ¹× N2 º´±âÀÇ ºñ¼Ò¼¼Æ÷¼º Æó¾Ï ȯÀÚ 92¸íÀ» ´ë»óÀ¸·Î ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. ȯÀÚ ³ª
ÀÌÀÇ ºÐÆ÷´Â 32¼¼ºÎÅÍ 78¼¼À̾ú´Ù. TNM º´±â¿¡ µû¸¥ ȯÀÚºÐÆ÷´Â 35¸íÀÌ Á¦ 2 º´±â, 57¸íÀÌ
Á¦ 3 º´±âÀ̾ú´Ù. N1 º´±âÀÇ È¯ÀÚ´Â 49¸íÀ̾ú°í N2º´±âÀÇ È¯ÀÚ´Â 43¸íÀ̾ú´Ù. 56¸íÀº T1~2
º´±âÀÇ Á¾¾ç¿¡ ¼ÓÇÏ¿´°í 36¸íÀº T3~4 º´±âÀÇ Á¾¾ç¿¡ ¼ÓÇÏ¿´´Ù. ÃÑ ¹æ»ç¼± Á¶»ç·®Àº 40 ³»
Áö 60 GyÀ̾úÀ¸¸ç ´ëºÎºÐÀÇ È¯ÀÚ´Â 50 Gy ¶Ç´Â 50.4 GyÀÇ ¹æ»ç¼±À» Á¶»ç ¹Þ¾Ò´Ù. ÃßÀû±â°£
Àº 9°³¿ù ³»Áö 7³âÀ̾úÀ¸¸ç Áß¾Ó°ªÀº 26°³¿ùÀ̾ú´Ù.
°á°ú: Àüü ȯÀÚ¿¡¼­ 3³â ¹× 5³â »ýÁ¸À²Àº 46% ¹× 38%À̾ú´Ù. 3³â ¹× 5³â ¹«º´»ýÁ¸À²Àº °¢
°¢ 44% ¹× 36%À̾ú´Ù. Á¦ 2 º´±â ȯÀÚ¿Í Á¦ 3 º´±âÀÇ È¯ÀÚ¿¡¼­ 5³â »ýÁ¸À²¿¡ À¯ÀÇÇÑ Â÷ÀÌ
°¡ ÀÖ¾ú´Ù(50% vs 28%). N1º´±â ¹× N2 º´±â ȯÀÚÀÇ 5³â »ýÁ¸À²Àº °¢°¢ 52% ¹× 20% À̾ú
´Ù. T1~2 º´±â ¹× T3~4 º´±â ȯÀÚ¿¡¼­´Â °¢°¢ 40% ¹× 34%À̾ú´Ù. Àüü ȯÀÚ¿¡¼­ ±¹¼Ò Àç
¹ßÀ²Àº 13%À̾ú°í, N1º´±â ¹× N2º´±â ȯÀÚ¿¡¼­ÀÇ ±¹¼Ò Àç¹ßÀ²Àº °¢°¢ 8% ¹× 18%À̾ú´Ù.
°á·Ð: º» ¿¬±¸´Â ºñ¼Ò¼¼Æ÷¼º Æó¾Ï ȯÀÚ¿¡¼­ ¼ö¼úÈÄ ¹æ»ç¼±Ä¡·á°¡ ±¹¼Ò Á¦¾îÀ²À» Çâ»ó½ÃÅ´À»
È®ÀÎÇÏ¿´´Ù. ±×·¯³ª ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á°¡ »ýÁ¸À²À» Çâ»ó½ÃÅ°Áö´Â ¸øÇÏ¿´´Ù. ¿ø°Ý ÀüÀ̸¦ ¿¹
¹æÇÏ¿© ±Ã±ØÀûÀ¸·Î »ýÁ¸À²À» Áõ°¡½Ãų ¼ö ÀÕ´Â º¸´Ù È¿°úÀûÀÎ Àü½Å¿ä¹ý °üÇÏ ¿¬±¸°¡ ÇÊ¿äÇÒ
°ÍÀ¸·Î »ý°¢µÈ´Ù.

Purpose: To evaluate effect of postoperative radiotherapy on survival and local control for patients with non-small cell lung cancer (NSCLC).
Materials and Methods: Ninety two NSCLC patients with N1 or N2 involvement who
were treated with postoperative radiotherapy following surgery with curative intent from
May 1987 to October 1999 were retrospectively analyzed. Age of the patients was
ranged from 32 to 78 years. According to TNM Stage, 35 patients had Stage ¥±and 57
had Stage ¥² disease. There were 49 patients with N1 involvement and 43 patients with
N2 involvement. Fifty six patients were noted to have T1~2 tumors and 36 patients to
have T3~4 tumors. Delivered total dose was ranged from 40 to 60 Gy. Majority of
patients received 50 Gy or 50.4 Gy. Follow-up period was ranged from 9 month to 7
years with median follow-up of 26 months.
Results: Overall survival rates at 3 and 5 years for entire group of patients were 46%
and 38%, respectively. corresponding disease free survival rates were 44% and 36%.
There was significant difference in survival between patients with Stage ¥±and Stage ¥²
disease (50% vs 28% at 5-year). Five year survival rates for N1 and N2 patients were
52% and 20%, respectively (p<0.05). These were 40% and 35% for patients with T1~2
tumors and T3~4 tumors. There were documented local relapses in 13% of the patients.
For patients with N1 and N2 Stage, local relapse rates were 8% and 18%, respectively.
Conclusion: Our study confirms that postoperative radiotherapy for patients with
non-small cell lung cancer improves local control. However, influence of postoperative
radiotherapy on long-term survival is less clear. More effective systemic treatment to
prevent distant metastasis should be investigated in future study to improve long-term
survival.

Å°¿öµå

¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á; ºñ¼Ò¼¼Æ÷¼º Æó¾Ï; Postoperative radiotherapy; Non-small cell lung cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS